Literature DB >> 1127735

Circulating interferon in man after administration of exogenous human leukocyte interferon.

G Emödi, M Just, R Hernandez, H R Hirt.   

Abstract

Interferon was measured at different intervals after the iv, sc, and im application of exogenous human leukocyte interferon to patients with various virus diseases or neoplasms. Interferon injected iv into patients had a half-life of about 15 minutes in the 1st hour and of about 90 minutes in the next 3 hours. Six hours after iv injection of 30 million U, no serum interferon was detectable. With a continuous iv infusion, a relatively high serum interferon level was reached. By the im administration of 1 million U interferon, a peak level of serum interferon (mean value 107 U/ml serum) occurred after 2 hours and was fairly stable for about 6 hours. Twenty-four hours after im application, a low level of serum interferon was still detectable. Similar results were found after sc interferon injections. In a patient with subacute sclerosing panencephalitis, no interferon was found in the cerebrospinal fluid at the time of the highest serum interferon level and 24 hours after two im interferon injections. Only minimal side reactions resulted from sc and im interferon injections. In one patient, a shock reaction occurred after iv application. For therapeutic trials, about 1 million U exogenous human interferon should be injected twice daily im or sc.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1127735

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

1.  Intracellular staining of Mx proteins in cells from peripheral blood, bone marrow and skin.

Authors:  A N al-Masri; T Werfel; D Jakschies; P von Wussow
Journal:  Mol Pathol       Date:  1997-02

Review 2.  Antiviral agents: action and clinical use.

Authors:  T W Chang; D R Snydman
Journal:  Drugs       Date:  1979-11       Impact factor: 9.546

Review 3.  Antiviral agents: an update--Part 2.

Authors:  S Bogger-Goren; P L Ogra
Journal:  Indian J Pediatr       Date:  1980 Nov-Dec       Impact factor: 1.967

Review 4.  Differences between human alpha (leukocyte) and beta (fibroblast) interferons.

Authors:  T G Hayes
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

Review 5.  Interferon therapy: pharmacokinetic and pharmacological aspects.

Authors:  A Billiau
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

Review 6.  Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.

Authors:  R B Pollard
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

7.  Clinical effect of interferon in malignant brain tumours.

Authors:  M Nagai; T Arai
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

8.  Acyclovir monotherapy versus acyclovir plus beta-interferon in focal viral encephalitis in children.

Authors:  U Wintergerst; B H Belohradsky
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

9.  A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion.

Authors:  A Z Rohatiner; F R Balkwill; D B Griffin; J S Malpas; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans.

Authors:  A Billiau; P De Somers; V G Edy; E De Clercq; H Heremans
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.